Bullish Case: Known: AMRN is flat (~$15.12) while AMRN IV surface shows much higher vol on deep puts than on higher strikes, implying upside convexity if price grinds up. SPY IV is comparatively smoother/lower, so tail risk looks idiosyncratic. Inferred: backwardation + Helium’s 74% bullish-risk skew favors mild re-rating. Uncertain: whether any July–Aug catalyst arrives to trigger near-term IV compression.

Bearish Case: Known: put volume dominates (568% puts vs calls) and AMRN IV stays extreme (400–500%) for far OTM puts across 2–20+ week tenor, matching the return surface’s thicker negative-likelihood band around -20% to -40%. Inferred: after Hikma/skinny-label legal relief, brand cash-flow and sentiment may lag. Uncertain: dilution/reimbursement headlines timing; if AMRN breaks ~$14, downside vol may not mean-revert.

Potential Outcomes:

1. 22%: by Jul17–Aug21 AMRN re-rates; ATM+call IV compresses while price holds >$15.8 (ACC/label/reimbursement positive).
2. 48%: range ±5% as IV decays with backwardation; calibrated down from prior ~25% upside (missed March–May rallies).
3. 20%: -12–-18% if dilution/reg surprise; deep-put IV (400–500%) stays elevated and AMRN closes < $14.5.
4. 7%: -30% tail on financing/partner shock plus break $13.5.
5. 3%: SPY risk-off lifts correlations.

Oracle: IV-down + $15+ favors call spreads; IV-up + $14 break favors put spreads.

July 10, 2026